CURRENT ISSUE

Genetic Engineering " Biotechnology News - Current Issue

(view larger image)

SUBSCRIBE

AD LINK

Visit GEN on Twitter!

GEN News Highlights

  • Print
  • Share
  • More GEN News Highlights

Nov 30 2009, 11:23 AM EST

ALS Foundations Fund Collaboration to Evaluate RXi’s Self-Delivering rxRNAs as Therapeutics

GEN News Highlights

Three research foundations dedicated to amyotrophic lateral sclerosis (ALS) research and drug development will jointly fund an ALS therapeutics collaboration between RXi Pharmaceuticals and researchers at the University of Massachusetts Medical School (UMMS) in Worcester.

The work, by RXi and Robert Brown, M.D., D.Phil, chair of the department of neurology at UMMS, aims to evaluate the use of RXi’s self-delivering rxRNA™ (sd-rxRNA™) compounds in the treatment of ALS. The research will be funded by The Angel Fund, the ALS Therapy Alliance, and Project ALS.

As part of the collaboration, Dr. Brown’s team will investigate the ability of RXi’s sd-rxRNA molecules to effect gene silencing and extend survival in a mouse model of familial ALS. According to Dr. Brown, while an RNAi-based approach to ALS therapy is theoretically promising, in practice it has been limited by issues associated with delivering the molecules. He maintains RXi’s sd-rxRNAs could represent “the unique solution that could be the key to treating neurological disorders such as ALS.”

RXi claims the fact that its proprietary rxRNA compounds are designed specifically for therapeutic use means that in comparison with conventional siRNAs, its molecules have a number of beneficial features. These include higher specificity for the target gene, a greater reliability at blocking immune side effects, up to 100-fold higher activity, and increased resistance to nuclear degradation.

 

♦♦♦
Related News

Johns Hopkins Gets $3.7M Two-Year Grant from NIH to Study ALS (Oct. 22, 2009)
Investigators Pinpoint Gene Variant Linked to ALS Progression (May 12, 2009)
Mutations of New Gene Trigger 5% of Inherited ALS Cases (Feb. 27, 2009)
Neuralstem's ALS Trial with Stem Cell Therapy Delayed (Feb. 20, 2009)
Extra Copy of Gene Prolongs Life in Mice with Inherited Form of ALS (Dec. 10, 2008)

  • Print
  • Share
  • More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:

HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.


CAREER CENTER

Visit the GEN Career Center

for the latest biotech employment opportunities.
Start your search HERE!

visit the Career Center

WEBINARS


view all webinars

GEN and Scintellix bring you the Cryptogram Challenge: RNAi!

PODCASTS

INTERVIEW: NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates ...MORE

MOST POPULAR

News

Articles

Blogs